![Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | British Journal of Cancer Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6601147/MediaObjects/41416_2003_Article_BF6601147_Fig1_HTML.gif)
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | British Journal of Cancer
![Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs - Milano - 2022 - Cancer Science - Wiley Online Library Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs - Milano - 2022 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d27f4171-f173-461a-8b32-294e36422791/cas15377-toc-0001-m.jpg?trick=1676854954369)
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs - Milano - 2022 - Cancer Science - Wiley Online Library
![Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer | Pharmacogenomics Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/14622416.9.5.539/asset/images/medium/graphic25.gif)
Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer | Pharmacogenomics
![Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time - European Journal of Cancer Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time - European Journal of Cancer](https://www.ejcancer.com/cms/asset/c47f313c-36a4-4ba7-b45b-5981074d0ddb/gr1.jpg)
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time - European Journal of Cancer
![Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ... Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...](https://www.thelancet.com/cms/attachment/2119213480/2090684064/gr1.gif)
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...
![Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study) Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)](https://www.spandidos-publications.com/article_images/ol/11/6/ol-11-06-4049-g00.jpg)
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
![First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer - The ASCO Post First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer - The ASCO Post](https://ascopost.com/media/14013635/10-table.jpg)
First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer - The ASCO Post
![Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/content/dmd/28/4/423/F1.large.jpg)
Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients | Drug Metabolism & Disposition
![All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide | JCO Oncology Practice All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide | JCO Oncology Practice](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/op/2022/op.2022.18.issue-4/op.21.00624/20220405/images/large/op.21.00624t3.jpeg)
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide | JCO Oncology Practice
![359 Erhöhte Irinotecan-Toxizität bei reduzierter UGT1A1-Aktivität - IMD Institut für medizinische Diagnostik, Labor 359 Erhöhte Irinotecan-Toxizität bei reduzierter UGT1A1-Aktivität - IMD Institut für medizinische Diagnostik, Labor](https://www.imd-berlin.de/fileadmin/user_upload/Diag_Info/359_Abb_1.png)
359 Erhöhte Irinotecan-Toxizität bei reduzierter UGT1A1-Aktivität - IMD Institut für medizinische Diagnostik, Labor
![Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study | BMC Cancer | Full Text Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5862-3/MediaObjects/12885_2019_5862_Fig5_HTML.png)
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study | BMC Cancer | Full Text
![Pharmacokinetics | ONIVYDE® (irinotecan liposome injection) | Metastatic Pancreatic Cancer | HCP | Onivyde Pharmacokinetics | ONIVYDE® (irinotecan liposome injection) | Metastatic Pancreatic Cancer | HCP | Onivyde](https://www.onivyde.com/sites/g/files/kcxpwu251/files/2022-08/Group%2078233.png)